SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


          [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACTS OF 1934

                For the quarterly period ended September 30, 2005

                                       or

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE
                        SECURITIES EXCHANGE ACTS OF 1934

      For the transition period from                 to
                                     ---------------    -------------

                        Commission File Number: 000-27931

                          DESERT HEALTH PRODUCTS, INC.
             (Exact name of registrant as specified in its charter)


                                     ARIZONA
      (State of other jurisdiction of other jurisdiction of incorporation or
                                  organization)


                                   86-0699108
                    (I.R.S. Employer Identification Number)


                 8221 EAST EVANS ROAD, SCOTTSDALE ARIZONA 85260
                    (Address of Principal executive office)

                                  480.951.1941
              (Registrant's telephone number, including area code)

                          ----------------------------

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.   Yes    X              No
                                                ------               -----

Indicate by check mark whether the registrant is a shell company (as defined in
Rule12b-2 of the Exchange Act).  Yes                  No   X
                                     -----               -----

The number of shares of Common Stock outstanding as of November 10, 2005:
17,608,521

Transitional Small Business Disclosure Format (check one):  Yes       No  X
                                                                -----    -----

<PAGE>

        DESERT HEALTH PRODUCTS, INC. CONSOLIDATED STATEMENTS (UNAUDITED)

                                FORM 10QSB INDEX

PART 1. FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited):

     a.   Consolidated  Balance  Sheets  as  of  September  30,  2005,       F-1
          and December 31, 2004

     b.   Consolidated Statements of Operations                              F-2
          for the three and nine month period ended September 2005
          and 2004

     c.   Consolidated Statements of Stockholders' Deficit                   F-3
          as of September 30, 2005 and December 31, 2004

     d.   Consolidated Statements of Cash Flow for the nine months ended     F-4
          September 30, 2005 and 2004

     e.   Notes to Unaudited Consolidated Financial Statements               3

Item 2. Management's Discussion and Analysis of Financial Condition
        and Results of Operations                                            4

Item 3. Controls and Procedures                                              9

PART II - OTHER INFORMATION

Item 1. Legal Proceedings                                                    9

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds           9

Item 3. Defaults by the Company Upon Its Senior Securities                   9

Item 4. Submission of Matters to a Vote of Security Holders                  9

Item 5. Other Information                                                    10

Item 6. Exhibits                                                             10

Signatures                                                                   10

<PAGE>

<TABLE>
<CAPTION>
                          DESERT HEALTH PRODUCTS, INC.
                    CONSOLIDATED BALANCE SHEETS (UNAUDITED)


                                                       SEPTEMBER 30,   DECEMBER 31,
                                                           2005             2004
                                                       -------------  -------------
<S>                                                         <C>            <C>
                                     ASSETS
 CURRENT ASSETS
   Cash                                                $      3,276   $      2,135
   Accounts receivable, net                                     186            175
   Inventory                                                 80,826         75,141
   Prepaids                                                       -          7,500
                                                       -------------  -------------
     Total Current Assets                                    84,288         84,951
                                                       -------------  -------------

 PROPERTY AND EQUIPMENT, NET                                 12,225         64,410
                                                       -------------  -------------

 OTHER ASSETS
   Deferred financing costs                                       -        129,122
                                                       -------------  -------------

     TOTAL ASSETS                                      $     96,513   $    278,483
                                                       =============  =============

                      LIABILITIES AND STOCKHOLDERS' DEFICIT
 CURRENT LIABILITIES
   Bank Overdraft                                      $      9,667   $        809
   Accounts payable and accrued expenses                    730,235        609,212
   Advances                                                 194,536              -
   Loan inducement fees payable                              11,340         11,340
   Deferred revenue                                          44,372         26,000
   Interest payable                                         647,590        417,246
   Dividends payable                                        274,387        274,387
   Current portion of notes payable                       2,356,748      1,935,193
                                                       -------------  -------------
     Total Current Liabilities                            4,268,875      3,274,187

 LONG TERM LIABILITIES
   Shares subject to mandatory redemption                 1,100,000      1,100,000
   Long term note payable, net of current portion           225,000        225,000
                                                       -------------  -------------

     TOTAL LIABILITIES                                    5,593,875      4,599,187
                                                       -------------  -------------

 COMMITMENTS AND CONTINGENCIES

 STOCKHOLDERS' DEFICIT
      Preferred Stock, convertible, $.001 par value,
      10,000,000 shares authorized, 3,319,125 and
      3,359,125 issued shares and outstanding as of
      September 30, 2005 and December 31, 2004, respectively

      Common Stock, $.001 par value, 25,000,000 shares
      authorized, 20,933,521 and 15,663,821 issued; and
      20,508,521 and 15,238,821 outstanding as of
      September 30, 2005 and December 31, 2004,
      respectively

      Stock subscribed                                      266,940        404,881
      Treasury stock, 425,000 shares at cost               (191,250)      (191,250)
      Additional paid in capital                         10,250,775      8,758,124
      Accumulated deficit                               (15,848,081)   (13,311,483)
                                                       -------------  -------------

     TOTAL STOCKHOLDERS' DEFICIT                         (5,497,362)    (4,320,704)
                                                       -------------  -------------

     TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT       $     96,513   $    278,483
                                                       =============  =============
</TABLE>

                                       F-1
<PAGE>

<TABLE>
<CAPTION>
                                     DESERT HEALTH PRODUCTS, INC.
                          CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)

                                                    THREE MONTHS ENDED          NINE MONTHS ENDED
                                                       SEPTEMBER 30,              SEPTEMBER 30,
                                               --------------------------  --------------------------
                                                   2005          2004          2005          2004
                                               ------------  ------------  ------------  ------------
<S>                                                <C>           <C>           <C>           <C>
  REVENUES, NET                                $    14,694   $    91,757   $    99,890   $   210,571

  COST OF REVENUES
    Merchandise                                      9,484        59,730        69,222       120,260
                                               ------------  ------------  ------------  ------------
                                                     9,484        59,730        69,222       120,260
                                               ------------  ------------  ------------  ------------

    Gross Profit                                     5,210        32,027        30,668        90,311

  OPERATING EXPENSES
    General and administrative                     347,618       354,738     2,004,012     1,335,260
    Impairment of intangibles                            -             -             -       756,822
    Impairment of goodwill                               -             -             -       233,645
                                               ------------  ------------  ------------  ------------
      Total operating expenses                     347,618       354,738     2,004,012     2,325,727
                                               ------------  ------------  ------------  ------------

    Net Loss From Operations                      (342,408)     (322,711)   (1,973,344)   (2,235,416)
                                               ------------  ------------  ------------  ------------

  OTHER INCOME (EXPENSE)
    Interest expense                              (240,839)     (191,961)     (570,107)   (1,026,106)
    Debt forgiveness                                 1,853             -         6,853             -
    Other income                                         -             -             -         8,653
                                               ------------  ------------  ------------  ------------
                                                  (238,986)     (191,961)     (563,254)   (1,017,453)
                                               ------------  ------------  ------------  ------------

  NET LOSS                                     $  (581,394)  $  (514,672)  $(2,536,598)  $(3,252,869)
                                               ============  ============  ============  ============

  BASIC & DILUTED LOSS  PER SHARE              $     (0.03)  $     (0.04)  $     (0.15)  $     (0.24)
                                               ============  ============  ============  ============

  WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    20,154,173    14,192,731    17,025,694    13,653,348
                                               ============  ============  ============  ============
</TABLE>

                                       F-2
<PAGE>

<TABLE>
<CAPTION>
                                                DESERT HEALTH PRODUCTS, INC
                                  CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (unaudited)


                                            Convertible Preferred Stock             Common Stock          Treasury Stock
                                       ------------------------------------  ---------------------------  -------------------
                                               Shares            Par Value      Shares       Par Value    Shares      Cost
                                       -----------------------  -----------  -------------  ------------  -------  ----------
<S>                                         <C>                      <C>          <C>            <C>           <C>      <C>
Balances,  December 31,  2004                       3,359,125        3,360     15,663,821        15,664   425,000   (191,250)

 Shares cancelled for the nine months
    ended September 30, 2005:                                                    (750,000)         (750)        -          -

 Shares issued for the nine months
    ended September 30, 2005:
   Loan inducement                                          -            -        275,000           275         -          -
   Services and fees                                        -            -      5,300,000         5,300         -          -
   Stock conversion                                   (40,000)         (40)        40,000            40         -          -
   Stock subscribed - issued                                -            -        404,700           405         -          -
   Stock subscribed                                         -            -              -             -         -          -
 Net loss for the nine months ended
    September 30, 2005                                      -            -              -             -         -          -
                                       -----------------------  -----------  -------------  ------------  -------  ----------
 Balances, September 30, 2005                       3,319,125   $    3,320     20,933,521   $    20,934   425,000  $(191,250)
                                       =======================  ===========  =============  ============  =======  ==========


                                           Additional paid-       Stock       Accumulated    Total Equity
                                              in Capital        Subscribed      Deficit       (Deficit)
                                       -----------------------  -----------  -------------  ------------
Balances,  December 31,  2004                       8,758,124      404,881    (13,311,483)   (4,320,704)

 Shares cancelled for the nine months
    ended September 30, 2005:                             750                                         -

 Shares issued for the nine months
    ended September 30, 2005:
   Loan inducement                                     51,975            -              -        52,250
   Services and fees                                1,219,950            -              -     1,225,250
   Stock conversion                                         -            -              -             -
   Stock subscribed - issued                          219,976     (220,381)             -             -
   Stock subscribed                                         -       82,440              -        82,440
 Net loss for the nine months ended
    September 30, 2005                                      -            -     (2,536,598)   (2,536,598)
                                       -----------------------  -----------  -------------  ------------
 Balances, September 30, 2005          $           10,250,775   $  266,940   $(15,848,081)  $(5,497,362)
                                       =======================  ===========  =============  ============
</TABLE>

                                                      F-3
<PAGE>

<TABLE>
<CAPTION>
                                      DESERT HEALTH PRODUCTS, INC
                                 CONSOLIDATED STATEMENTS OF CASH FLOW
                                For The Nine Months Ended September 30,
                                             (Unaudited)


                                                                               2005          2004
                                                                           ------------  ------------
<S>                                                                            <C>           <C>
 CASH FLOWS FROM OPERATING ACTIVITIES
   Loss from operations                                                    $(2,536,598)  $(3,252,869)
   Adjustments to reconcile net loss to net cash in operating activities:
     Depreciation                                                               52,185        14,062
     Preferred Stock issued for interest payment                                     -       124,094
     Shares issued for financing costs                                         255,794       410,731
     Impairment of intangibles and goodwill                                          -       990,467
     Stock issued for services and fees                                      1,225,250       443,000
     Bad debt expense                                                           37,199             -
     Other                                                                      (6,853)            -
   Change in:
     Accounts receivable                                                       (37,210)       (9,631)
     Inventory                                                                  (5,685)       11,852
     Prepaid expenses                                                            7,500        (7,500)
     Accounts payable                                                          122,876       185,568
     Deferred revenue                                                           18,372        (5,481)
     Bank overdraft                                                              8,858             -
     Interest payable                                                          290,917       134,303
                                                                           ------------  ------------

          Net Cash Used in Operating Activities                               (567,395)     (961,404)
                                                                           ------------  ------------
 CASH FLOWS FROM INVESTING ACTIVITIES
   Purchase of intangibles                                                           -        (3,442)
   Deposits                                                                      1,250
                                                                           ------------

     Net Cash Used in Investing Activities                                           -        (2,192)
                                                                           ------------  ------------

 CASH FLOWS FROM FINANCING ACTIVITIES
   Proceeds from notes payable                                                 315,000       421,400
   Proceeds from advances                                                      194,536             -
   Increase in paid in capital                                                       -        17,325
   Payments on notes payable                                                   (16,000)      (38,659)
   Payments on advances                                                              -        (1,000)
   Proceeds from sale of stock                                                       -       185,000
   Cash received for unissued shares                                            75,000       368,110
                                                                           ------------  ------------

     Net Cash Provided by Financing Activities                                 568,536       952,176
                                                                           ------------  ------------

     Net Decrease in Cash and Cash Equivalents                                   1,141       (11,420)

 BEGINNING CASH AND CASH EQUIVALENTS                                             2,135        11,420
                                                                           ------------  ------------

 ENDING CASH AND CASH EQUIVALENTS                                          $     3,276   $         -
                                                                           ============  ============
</TABLE>

                                       F-4
<PAGE>

Notes to Financial Statements

Note 1. Summary Of Significant Accounting Policies

Basis of Presentation and Interim Consolidated Financial Statements

     The accompanying unaudited condensed consolidated balance sheet as of
September 30, 2005 and the related unaudited condensed consolidated statements
of operations, stockholders' deficit and cash flows for the nine months ended
September 30, 2005 and 2004 presented herein have been prepared in accordance
with accounting principles ("GAAP") generally accepted in the United States of
America for interim financial information and in accordance with the
instructions to Form 10-QSB.  Accordingly, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted. In
our opinion, the accompanying condensed consolidated financial statements
include all adjustments necessary for a fair presentation of such condensed
consolidated financial statements.  Such necessary adjustments consist of normal
recurring items and the elimination of all significant intercompany balances and
transactions.

     These interim condensed consolidated financial statements should be read in
conjunction with Desert Health's  December 31, 2004, Annual Report on Form
10-KSB.  Interim results are not necessarily indicative of results for a full
year. Certain reclassifications have been made to conform prior period
financials to the presentation in the current reporting period.  The
reclassifications had no effect on net loss.

     The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statement and the reported amounts of revenues and expenses during the reporting
period.  Actual results could differ from these estimates.

Stock  Based  Compensation

     Desert Health  has elected to follow Accounting Principles Board Opinion
No. 25, "Accounting for Stock Issued to Employees" (APB 25) and the related
interpretations in accounting for its employee stock options. Under APB 25,
because the exercise price of employee stock options equals or exceeds the
market price of the underlying stock on the date of grant, no compensation
expense is recorded. Desert Health has adopted the disclosure-only provision of
Statement of Financial accounting Standards No. 123., "Account for Stock Based
Compensation".

     Desert  Health  has no issuances of stock options for the periods presented
and,  as  such  has  no  pro  forma  earnings  per  share  presentation.

Note  2.  New  Financing

     During the nine months ended September 30, 2005, Desert Health obtained new
short term financing from individuals in the total amount of $315,000  bearing
interest at 7% APR to 20% APR.  During the nine months ended September 30, 2005,
Desert Health received advances from individuals in the amount of $194,536.

Note 3. Stock Issuances

     On May 2, 2005, Desert Health established the 2005 Directors, Officers and
Consultants Stock Option, Stock Warrant and Stock Award Plan.  Under the Plan,
Desert Health is authorized to issue up to a maximum of 6,000,000 shares of
common stock.

     During the nine months ended September 30, 2005, the Desert Health issued
5,300,000 common shares to consultants for professional services valued at
$1,225,250.

                                        3
<PAGE>

     Desert Health also issued 275,000 common shares to debt holders as loan
inducements valued at $52,250 and has not issued 62,000 shares valued at $7,440
for loan expenses. Desert Health also received $75,000 for 500,000 common shares
not yet issued as of September 30, 2005.

Note 4.  Subsequent Events

     Subsequent to September 30, 2005, Desert Health issued 550,000 shares to
consultants for professional services valued at approximately $60,500.

     At  a stockholders meeting on October 26, 2005, shareholders authorized the
proposal  of  management to amend the Articles of Incorporation of Desert Health
to  increase  the  number  of  common  shares  authorized  from  25,000,000  to
100,000,000.

     In October 2005, there were 3,875,000 shares cancelled due to a breach of
an agreement.


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

     Unless the context otherwise requires, the terms "Desert Health",
"Company", "we", "us" and "our" in this Quarterly Report on Form 10-QSB refer to
Desert Health Products, Inc., an Arizona corporation.

     The following discussion and analysis should be read in conjunction with
our Financial Statements and the notes thereto appearing elsewhere in this
document.

Cautionary Statement Regarding Forward-looking Statements

     Our Annual Report on Form 10-KSB, this or any other quarterly reports on
Form 10-QSB filed by us or any other written or oral statements made by or on
our behalf may include forward-looking statements which reflect our current
views with respect to future events and financial performance. The words
"believe", "expect", "anticipate", "intends", "estimate", "forecast", "project"
and similar expressions identify forward-looking statements.

     We wish to caution investors that any forward-looking statements made by or
on our behalf are subject to uncertainties and other factors that could cause
actual results to differ materially from such statements. These uncertainties
and other factors include, but are not limited to the Risk Factors which have
been discussed in prior filings with the Securities and Exchange Commission
("SEC"). The following factors, among others, could cause actual results to
differ from those indicated in the forward-looking statements:

     o    The gain or loss of significant customers or significant changes
          in purchasing volume;

     o    The amount and timing of our operating expenses and capital
          expenditures;

     o    Changes in the volume of our product sales and pricing
          concessions on volume sales;

     o    The timing, rescheduling or cancellation of customer orders;

     o    The varying length of our sales cycles;

     o    Our ability to specify, develop, complete, introduce and market
          new products and bring them to volume production in a timely manner;

     o    The rate of adoption and acceptance of new industry standards in
          our target markets;

                                        4
<PAGE>

     o    The effectiveness of our product cost reduction efforts and those
          of our suppliers;

     o    Changes in the mix of products we sell;

     o    Changes in the average selling prices of our products; and

     o    The risk factors described in other documents and reports filed
          with the SEC, including our Annual Report on Form 10-KSB for the year
          ended December 31, 2004.

     Though we have attempted to list comprehensively these important factors,
we wish to caution investors that other factors could in the future prove to be
important in affecting our results of operations. New factors emerge from time
to time and it is not possible for management to predict all of such factors,
nor can it assess the impact of each such factor on the business or the extent
to which any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking statements.

     Investors are further cautioned not to place undue reliance on such
forward-looking statements as they speak only of our views as of the date the
statement was made. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

OVERVIEW

     We are engaged in the packaging, sale and distribution of branded and store
brand (private label) vitamins, nutritional supplements, skin care and animal
care products. We have focused our marketing and registration efforts primarily
in the foreign marketplace. This is a very time consuming and expensive project,
but the nutraceutical and nutritional supplement market is growing at a faster
pace internationally than the domestic market. One of the many rewards of having
customers in the international market is that once the registrations are in
place, the customer becomes a partner in developing that market in the
long-term.  However, we are taking steps to offer our products to mid-size chain
store operations as an initial step towards penetrating the domestic market.

       We market over 100 products, which are packaged under various labels and
bottle counts. They are sold in Vitamin and Mineral combinations, Chinese Herbal
Products, Specialty Supplements, Weight Management Products, Herbal/Botanical
Products, FemAid Product Support Systems, Ayurvedic Products, Skin Care
Products, Pet Care Products, and Water Purification Products.  We have
traditionally outsourced our raw materials manufacturing.

     On January 26, 2000, pursuant to an Acquisition Agreement and Plan of
Merger entered into by and between Desert Health and Intercontinental Capital
Fund, Inc., ("Intercontinental"), a Nevada corporation (a company subject to the
reporting requirements of the Securities and Exchange Act of 1934, as amended)
all of the outstanding shares of common stock of Intercontinental were exchanged
for 400,000 shares of Rule 144 restricted common stock of Desert Health, in a
transaction in which Desert Health was the successor and took on the reporting
requirements of Intercontinental.

CRITICAL ACCOUNTING POLICIES

     This summary of critical accounting policies is presented to assist in
understanding our financial statements.  The financial statements and notes are
representations of our management who is responsible for their integrity and
objectivity.  These accounting policies conform to generally accepted accounting
principals and have been consistently applied in the preparation of the
financial statements.

                                        5
<PAGE>

Basis of Consolidation

     The consolidated financial statements include the accounts of Royal
Products, Inc., a wholly owned subsidiary.  All significant intercompany
accounts and transactions have been eliminated in the consolidation.


Depreciation

     Depreciation  is  computed  by using the straight-line method for financial
reporting  purposes  and the accelerated cost recovery method for federal income
tax  purposes

Revenue  and  Cost  Recognition

     Revenues  are  recognized  when  earned,  and  expenses are recognized when
incurred.  We  generally  recognize  revenue  upon  shipment  of our products in
accordance  with  the  terms and conditions of firm orders placed with us by our
customers

RESULTS  OF  OPERATIONS.

     Three  months  ended  September  30,  2005  and  2004

     Revenues. Revenues for the three months ended September 30, 2005 were
$14,694, a decrease of $77,063 or 84%, from $91,757 for the three months ended
September 30, 2004. This decrease is principally attributable to the stopping of
funding by a major investor in the fourth quarter of 2004. This funding was
partially for support of Desert Health's sales projects that were in place for
2005. Other funding sources are being pursued. There has been increased
acceptance of our registrations in the foreign markets and continuing
penetration into the domestic market. We are expecting the results of these
efforts to come to fruition in the fourth quarter 2005 and in 2006. We are
continuing our efforts to launch new distribution outlets in Europe, Asia and in
the domestic market.

     Gross Profit Margin. Gross profit was $5,210 or 35% for the three months
ended September 30, 2005, a decrease of $26,817 or 84%, from $32,027 or 35% for
the three months ended September 30, 2004. This decrease is primarily the result
reduced sales for the quarter. -

     Operating Expenses. Operating expenses for the three months ended September
30, 2005 were $347,618, a decrease of $7,120 or 2%, from $354,738 for the three
months ended September 30, 2004.

     Interest Expense. Interest expense for the three months ended September 30,
2005 was $240,839 an increase of $48,878 or 25%, from $191,961 for the three
months ended September 30, 2004. The increase is primarily the result of
accruing additional interest and principle as a result of a court ruling.

     Net Income (Loss). Net loss was $581,394 for the three months ended
September 30, 2005, as compared to a net loss of $514,672 for the three months
ended September 30, 2004. This increase is primarily the result of decreased
sales as discussed in the revenue section

     Nine Months Ended September 30, 2005 and 2004

     Revenues. Revenues for the nine months ended September 30, 2005 were
$99,890, a decrease of $110,681, or 53% decrease from $210,571 for the nine
months ended September 30, 2004. This decrease is principally attributable to
the stopping of funding by a major investor in the fourth quarter of 2004. This
funding was partially for support of Desert Health's sales projects that were in
place for 2005. Other funding sources are being pursued. There has been
increased acceptance of our registrations in the foreign markets and continuing
penetration into the domestic market. We are expecting the results of these
efforts to come to fruition in the fourth quarter 2005 and in 2006. We are
continuing our efforts to launch new distribution outlets in Europe, Asia and in
the domestic market.

                                        6
<PAGE>

     Gross Profit Margin. Gross profit was $30,668 or 31%, for the nine months
ended September 30, 2005, a decrease of $59,643 or 66% from $90,311 or 43%, for
the nine months ended September 30, 2004.  This decrease is primarily the result
of decreased sales in the first and third quarters and costs associated with
distribution of marketing samples.
                                 -

     Operating Expenses. Operating expenses for the nine months ended September
30, 2005 were $2,004,012, a decrease of $321,715 or 14% from $2,325,727 for the
nine months ended September 30, 2004. In 2004 approximately $1,000,000 of
operating expenses were the result of the complete write-off of intangibles to
comply with generally accepted accounting principles.

     Interest Expense. Interest expense for the nine months ended September 30,
2005, was $570,107 a decrease of $455,999, or 44%, from $1,026,106 for the nine
months ended September 30, 2004. The difference is primarily the result of
decreased levels of deferred financing costs and decreased levels of loan
inducement fees.

     Net Income (Loss). Net loss was $2,536,598 for the nine months ended
September 30, 2005, as compared to a net loss of $3,252,869 for the nine months
ended September 30, 2004. This decrease is primarily the result of the matters
discussed in the Revenue, Operating Expenses and the Interest Expense sections
above.

Liquidity and Capital Resources

     As indicated in our attached financial statements, our gross revenue was
not sufficient to meet our operating expenses for the nine months ended
September 30, 2005. In addition, as of September 30, 2005, our current
liabilities exceeded our current assets by $4,184,587 as compared to $2,786,298
for the comparable three month period ended September 30, 2004.

      Since inception, we have financed our cash flow requirements through debt
financing, issuance of common stock for cash and services, and minimal cash
balances. As we continue our marketing activities in Europe, China and North
America, we will continue to experience net negative cash flows from operations,
pending receipt of sales revenues, and will be required to obtain additional
financing to fund operations through common and preferred stock offerings and
bank borrowings to the extent necessary to provide working capital.

     Over the next 12 months, we intend to increase our revenues by releasing
new products under development to our target markets. We believe that existing
capital and anticipated funds from operations will not be sufficient to sustain
operations and planned expansion in the next 12 months. Consequently, we will be
required to seek additional capital in the future to fund growth and expansion
through additional equity or debt financing or credit facilities. Considering
the state of market conditions, no assurance can be made that such financing
would be available, and if available it may take either the form of debt,
equity, or a combination thereof. The down turn in the capital market will
substantially impact our ability to sell securities in planned amounts and in
turn our ability to meet our capital requirements. In either case, the financing
could have a negative impact on our financial condition and our stockholders.

     A fast growing segment of the over fifty billion dollar U.S. nutritional
supplement market is being reached through the use of infomercials.  Thus, we
have entered into a joint venture to participate in this form of marketing with
our new Celadrin Pain Management System, our Foot Care skin care system, and our
doctor tested and approved anti-aging products. These items are also being
offered to private label customers.

     During fourth quarter 2005, we are continuing to develop Royal Products,
Inc., a wholly owned subsidiary, which promotes sales in the network marketing
arena. Desert Health is negotiating for new management to develop Royal Products
into an into an international direct selling company. According to a report in
the July 2005 Direct Selling News magazine the direct sales industry's sales
volume on a global basis exceeded a record-setting $93 billion in 2004. We
believe that Royal Products will become a major factor in Desert Health's
business progress in 2006. Interest in this form of product sales is increasing

                                        7
<PAGE>

as can be seen by the success of major network marketing companies such as
Forever Living, Herbalife, Shaklee and others.

     There is increasing interest in our product lines from the international
markets. We have orders from our Middle East and United Kingdom customers and
have renewed the lease for the coming year at our office in Beijing, China, and
we are also becoming more aggressive in the domestic market.

     Management believes the implementation of events as described above will
bring liquidity and profitability to the Company in the coming year. We believe
exclusive marketing rights to the new health products, and other products being
negotiated for, will bring significant volume and profitability.

     We will increase the number of our employees, and expand our facilities
where necessary to meet product development and completion deadlines. We believe
that existing capital and anticipated funds from operations will not be
sufficient to sustain operations and planned expansion in the next 12 months.
Consequently, we will be required to seek additional capital in the future to
fund growth and expansion through additional equity or debt financing or credit
facilities. Considering the state of market conditions, no assurance can be made
that such financing would be available, and if available it may take either the
form of debt, equity, or a combination thereof.  A down turn in the capital
market will substantially impact our ability to sell securities in planned
amounts and in turn our ability to meet our capital requirements. In either
case, the financing could have a negative impact on our financial condition and
that of our shareholders.

RECENT DEVELOPMENTS

      In October 2005, we received another order for immediate delivery from one
of our major customers for $25,850, and an additional order of another product
for $48,000 for delivery in the first quarter of 2006. This customer has advised
us that their market is expanding and they intend to add three to five new
products from our product lines within the next two years.

     On September 28, 2005, we signed a contract with Military Resale Group,
Inc. (OTC:MYRG) a regional marketer and distributor of food and consumer goods
to the military, giving them the exclusive rights for the distribution of our
complete line of health and wellness products to all branches of the U.S.
Government. MYRG can sell our products to the Army, Air Force, Marines, Navy,
Coast Guard, Department of Defense, AAFES, the Defense Commissary System and the
Army Air force Exchange System. Joanne Cavanagh, H.N.T., A.H.G. will begin a
special training and education program of MYRG personnel in January 2006.

     May 3, 2005, we issued a press release announcing that we have entered into
an agreement with Wilkerson Creative, Inc., a producer of Direct Response Radio,
TV Commercials and Infomercials. Wilkerson Creative, Inc., has agreed to create
direct response radio and television commercials as well as radio and television
infomercials and to enter into arrangements with entities to cause such
commercials and infomercials to be aired. Additionally, we believe that
Wilkerson Creative, Inc. will provide the necessary talent to contribute to the
success of these projects.

     The first of three infomercials scheduled for airtime will focus on Desert
Health's Celadrin -based pain and joint support products. With recent
disclosures by the FDA concerning some pharmaceutical medications for arthritis
and pain relief either being removed from the market, or warnings being posted,
this natural pain relief product is being released in timely fashion.  Over 70
million individuals in the U.S. have arthritis. The Arthritis Foundation reports
that arthritis is the leading disability of Americans, resulting in over 39
million medical visits per year and $65 billion dollars annually in medical
expenses and lost wages.

     The second scheduled set of media attention through Wilkerson Creative,
Inc., will concentrate on Desert Health's Anti-Aging Cream. Clinical studies
conducted by dermatologist, Dr. Eugene Conte, concluded that patients responded
to treatment with remarkable skin improvement and consumer approval. The last
set of media scheduled for completion by Wilkerson Creative, Inc., will focus on
Desert Health's Foot and Body Care system.  This skin care system was designed

                                        8
<PAGE>

specifically to treat the dry skin and other conditions often associated with
diabetes. Unlike most exfoliation processes, this system is non-irritating, yet
highly effective .The following actions apply to this skin care system:
Cleanser; Incredible exfoliant; Antixoidant; Enhances natural skin repair;
Potent invigorator; Fantastic moisturizer.

     Rayfield Wright continues to be a supportive member of the quest for
optimal health through Wright's Sports and Nutrition's line of natural health
supplements. These supplement and skin care lines were designed and formulated
exclusively by Desert Health Products, Inc., for Wright's Sports and Nutrition,
LLC.

     The website address for Desert Health Products, Inc. is
www.deserthealth.com
                   -

ITEM 3. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

     As of September 30, 2005, our Chief Executive Officer, or "CEO", and Chief
Financial Officer, or "CFO", performed an evaluation of the effectiveness and
the operation of our disclosure controls and procedures as defined in Rules 13a
- 15 (e) or 15d-15 (e) under the Securities Exchange Act of 1934, as amended
(the "Exchange Act"). Based on that evaluation, the CEO and CFO concluded that
our disclosure controls and procedures were effective as of September 30, 2005.

CHANGES IN INTERNAL CONTROLS

     There have been no changes in our internal control over financial reporting
identified in connection with the evaluation required by paragraph (d) of Rule
13a-15 or 15d-15 under the Exchange Act that occurred during the quarter ended
September 30, 2005, that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.

                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

     Nicholas M. Simak and NMS Solutions Group, Inc., filed a complaint in
Maricopa County  Superior Court of the State of Arizona against the Company on
May 11, 2004, alleging non-payment of various loans.   This case had been
consolidated with a suit filed June 2, 2002 in the Maricopa County Superior
Court in the state of Arizona by a plaintiff holding an assignment of a note in
the amount of $50,000  from Nicholas M. Simak/NMS Solutions Group, Inc. It is
the company's position the note was repaid with issuance of stock in 2000.
Through the litigation process Desert Health won nine and lost seven of the
claims. It is currently in process waiting for findings of fact and conclusions
of law and a judgment.

      Please see our Annual Report filed on Form 10-KSB for the period ended
December 31, 2004, and our quarterly Reports filed on Form 8-KSB for the periods
ended March 31, 2005 and June 30, 2005 respectively, for discussion of pending
legal proceedings.

ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

     None

ITEM 3. DEFAULTS BY THE COMPANY UPON ITS  SENIOR SECURITIES

     None.

                                        9
<PAGE>

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     None.

ITEM 5. OTHER INFORMATION

      None.

ITEM 6. EXHIBITS

(a)     Exhibits

Registrant is filing the following exhibits:

31.1.     Certification of Chief Executive Officer pursuant to Item 601(b)(31)
          of Regulation S-B, as adopted pursuant to Section 302 of the
          Sarbanes-Oxley Act of 2002

31.2.     Certification of Chief Financial Officer pursuant to Item 601(b)(31)
          of Regulation S-B, as adopted pursuant to Section 302 of the
          Sarbanes-Oxley Act of 2002

32.1.     Certification of Chief Executive Officer pursuant to 18 U.S.C. Section
          1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002

32.2.     Certification of Chief Financial Officer pursuant to 18 U.S.D. Section
          1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
          2002


                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.

DESERT HEALTH PRODUCTS, INC.
(Registrant)

By:     /s/ Johnny Shannon               November 14, 2005
        ------------------
        Johnny Shannon,
        President

By:     /s/ Johnny Shannon               November 14, 2005
        ------------------
        Johnny Shannon,
        Chief Financial Officer

                                       10
<PAGE>